Table 3.
Recent clinical trials of CAR-T cell therapy for GBM treatment.
| Identifier | Title | Phase | Treatment approach | Patient type | Status |
|---|---|---|---|---|---|
| NCT01454596 | A phase 1/2 study of the safety and feasibility of administering T cells expressing Anti-EGFRvIII chimeric antigen receptor to patients with malignant gliomas expressing EGFRvIII | 1/2 | EGFRvIII-CARs | Malignant glioma (EGFRvIII-positive) | Completed |
| NCT02208362 | Genetically modified T-cells in treating patients with recurrent or refractory malignant glioma | 1 | IL13Rα2-CARs | Recurrent or refractory malignant glioma | Active |
| NCT01082926 | Phase 1 study of cellular immunotherapy for recurrent/refractory malignant glioma using intratumoral infusions of GRm13Z40-2, an allogenic CD8+ cytolitic T-cell line genetically modified to express the IL13-zetakine and HyTK and to be resistant to glucocorticoids in combination with interleukin-2 | 1 | GRm13Z40-2 interleukin-2 |
Recurrent/refractory malignant glioma | Completed |
| NCT01109095 | Administration of HER2 chimeric antigen receptor expressing CMV-specific cytotoxic T cells in patients with glioblastoma multiforme (HERT-GBM) | 1 | HER2-CARs | Recurrent or progressive GBM | Completed |
| NCT05063682 | A Phase 1 Study to Evaluate EGFRvIII -Targeted Chimeric Antigen Receptor (CAR) T Cells for Adult Patients With Leptomeningeal Glioblastoma | 1 | EGFRvIII-CAR T | leptomeningeal GBM | Active |
| NCT03726515 | Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma | 1 | CART-EGFRvIII Pembrolizumab |
nGBM (Unmethylated MGMT, EGFRvIII-positive) | Completed |
Data from ClinicalTrials.gov.